Bulletin
Investor Alert

Market Pulse Archives

Oct. 18, 2021, 8:32 a.m. EDT

Revance Therapeutics plummets after FDA said it can't approve BLA of treatment for frown lines

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Revance Therapeutics Inc. (RVNC)
  • X
    iShares Biotechnology ETF (IBB)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Shares of Revance Therapeutics Inc. /zigman2/quotes/202924160/composite RVNC +4.30% plummeted 34.7% toward an 18-month low in premarket Monday, which puts them on track for a record one-day selloff, after the company said the the Food and Drug Administration issued a Complete Response Letter (CRL) regarding the biotechnology company's treatment of glabellar, or frown, lines. The company said late Friday that FDA determined it could not approve the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection in its present form, citing deficiencies related to an inspection of Revance's manufacturing facility. The announcement comes after the company said late on Oct. 12, after Revance's stock plunged 25.1% that day, that it continued to expect the FDA to approve DaxibotulinumtoxinA for Injection this year. The stock, which is on track to open at the lowest price seen during regular-session hours since April 2020, has dropped 19.9% year to date through Friday, while the iShares Biotechnology ETF /zigman2/quotes/206189322/composite IBB +0.33% has gained 3.7% and the S&P 500 /zigman2/quotes/210599714/realtime SPX +1.42% has rallied 19.0%.

/zigman2/quotes/202924160/composite
US : U.S.: Nasdaq
$ 14.80
+0.61 +4.30%
Volume: 1.04M
Dec. 2, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.02 billion
Rev. per Employee
$32,606
loading...
/zigman2/quotes/206189322/composite
US : U.S.: Nasdaq
$ 151.23
+0.49 +0.33%
Volume: 1.92M
Dec. 2, 2021 4:00p
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,577.10
+64.06 +1.42%
Volume: 2.80B
Dec. 2, 2021 5:08p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.